Comparing Trinity Capital (NASDAQ:TRIN) & CERo Therapeutics (NASDAQ:CERO)

Trinity Capital (NASDAQ:TRINGet Free Report) and CERo Therapeutics (NASDAQ:CEROGet Free Report) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Earnings & Valuation

This table compares Trinity Capital and CERo Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Trinity Capital $181.85 million 4.02 $76.89 million $1.61 9.18
CERo Therapeutics N/A N/A N/A N/A N/A

Trinity Capital has higher revenue and earnings than CERo Therapeutics.

Insider and Institutional Ownership

24.6% of Trinity Capital shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 6.4% of Trinity Capital shares are owned by company insiders. Comparatively, 15.8% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Trinity Capital and CERo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Capital 36.12% 16.73% 7.57%
CERo Therapeutics N/A N/A N/A

Analyst Recommendations

This is a summary of current ratings and price targets for Trinity Capital and CERo Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Capital 0 1 5 0 2.83
CERo Therapeutics 0 0 0 0 N/A

Trinity Capital presently has a consensus target price of $15.50, indicating a potential upside of 4.87%. Given Trinity Capital’s higher probable upside, analysts plainly believe Trinity Capital is more favorable than CERo Therapeutics.

Risk & Volatility

Trinity Capital has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500.

Summary

Trinity Capital beats CERo Therapeutics on 7 of the 9 factors compared between the two stocks.

About Trinity Capital

(Get Free Report)

Trinity Capital Inc. is a business development company. It is a venture capital firm specializing in venture debt to growth stage companies looking for loans and/or equipment financing. Trinity Capital Inc. was founded in 2019 is based in Phoenix, Arizona with additional offices in the United States.

About CERo Therapeutics

(Get Free Report)

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Receive News & Ratings for Trinity Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Capital and related companies with MarketBeat.com's FREE daily email newsletter.